Peptide Stacks and Blends: Every Combination and Its Evidence
Every peptide stack and blend on one page: KLOW, GLOW, Wolverine, CJC-1295 + ipamorelin and more, with what is in each and whether it has been tested.
The short version
This page lists every peptide stack and blend I cover, grouped by goal. For each it shows what is in it, how it is sold and whether the combination has been tested. Only one has been tested in large human trials: CagriSema, a Novo Nordisk weight-loss drug still awaiting FDA approval. None of the research-peptide stacks, including KLOW, GLOW, the Wolverine stack and CJC-1295 with ipamorelin, has a human trial of the combination.
- CagriSema is the only combination here tested in large human trials, and it is not yet FDA-approved.
- No research-peptide stack, from KLOW to CJC-1295 with ipamorelin, has a human trial of the combination.
- A blend vial fixes the ratio; separate vials let each peptide be dosed on its own schedule.
- Any stack protocol on this site is labelled common practice, not trial-established.
Only one peptide combination has been tested in large human trials: CagriSema, Novo Nordisk’s mix of cagrilintide and semaglutide, which is still awaiting FDA approval. Every other stack below, including KLOW, GLOW, the Wolverine stack and CJC-1295 with ipamorelin, has no human trial of the combination.
Each row links to the stack’s own page, with its ingredients, vial maths and the doses people use. Those doses are labelled common practice, not trial-established.
Every peptide stack and blend, by goal
“Combination tested?” asks whether any study has given the stack’s ingredients together. “Ingredient evidence” is each peptide’s own human evidence, from its compound page.
Healing and recovery
| Stack | How it is sold | Combination tested? | Ingredient evidence | What to know |
|---|---|---|---|---|
| KLOWVendors and prices | One pre-mixed vial | No | A vendor-mixed vial of four research peptides. No study has tested the four together. | |
| GLOWVendors and prices | One pre-mixed vial | No | KLOW without the KPV. No study has tested the three together. | |
| Wolverine stackVendors and prices | One vial or two | Animals only | No human trial of the pair. The one animal study found it did no better than TB-500 alone. | |
| BPC-157 + KPV | Separate vials | No | Usually run as two vials. No study, human or animal, has tested them together. | |
| Tri-Heal | One pre-mixed vial | No | A 45 mg vendor blend. No human or animal study has tested the three together. |
Growth hormone
| Stack | How it is sold | Combination tested? | Ingredient evidence | What to know |
|---|---|---|---|---|
| CJC-1295 + ipamorelinVendors and prices | One vial or two | No |
| The most common pairing, often one 10 mg vial. No human study has given the two together. |
| Tesamorelin + ipamorelin | One vial or two | No |
| Tesamorelin is FDA-approved; ipamorelin has no approved product. No trial of the combination. |
| CJC-1295 DAC + ipamorelin | Separate vials | No |
| Two vials on two schedules: DAC weekly, ipamorelin daily. Not a tested combination. |
| CJC-1295 + GHRP-2 | One pre-mixed vial | No | Usually one 10 mg vial, 5 mg of each. No human study has given the two together. |
Weight loss
| Stack | How it is sold | Combination tested? | Ingredient evidence | What to know |
|---|---|---|---|---|
| CagriSema | Fixed-dose trial drug | Yes: Phase 3 trials |
| Novo Nordisk's fixed-dose combination, tested in Phase 3 trials and awaiting an FDA decision. |
| AOD-9604 + CJC-1295 + ipamorelin | One pre-mixed vial | No |
| A 12 mg blend vial. No published human study has given the three together. |
Other pairings
| Stack | How it is sold | Combination tested? | Ingredient evidence | What to know |
|---|---|---|---|---|
| Melanotan II + PT-141 | Separate vials | No |
| Two drugs on the same receptor family. PT-141 is FDA-approved; Melanotan II is not. |
| Semax + Selank | Separate vials | No | Two Russian nootropic peptides. One guide covers both. |
What is the best peptide stack?
By human evidence, CagriSema is the only stack here with large trials behind it. It is a weight-loss drug from a manufacturer, not a research blend, and the vials sold online as “research CagriSema” are a different, unreviewed product. See CagriSema dosage.
For muscle, no stack has been tested as a combination in people. The usual pairing, CJC-1295 with ipamorelin, raises growth hormone in small studies that did not measure muscle. Best peptides for muscle growth ranks the single compounds by their human evidence.
For healing, the Wolverine stack is the best known. Its one animal study found the pair did no better than TB-500 alone, and no human trial exists.
Blend vial or separate vials
A blend puts two to four peptides in one vial at a fixed ratio. That makes it simpler to draw, but one peptide’s dose cannot change without changing the others.
Separate vials let each peptide follow its own schedule. CJC-1295 DAC is taken weekly and ipamorelin daily, which a blend cannot do.
A blend also needs more from its certificate of analysis: identity and amount for every peptide in the vial, not one purity figure for the whole. See how to read a COA.
Why people stack
The appeal is easy to follow. BPC-157’s animal literature shows consistently positive healing effects across many soft-tissue injury types. Gwyer 2019 - Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159., in the references below People pair it with TB-500 on the idea that the two together speed recovery beyond either alone. That is a reasonable hypothesis, but it has not been tested in people.
What the evidence covers
- The research peptides in these stacks have no approved human evidence package for the marketed use. BPC-157 reviews still say human efficacy is unconfirmed. Gwyer 2019 - Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159., in the references belowJózwiak 2025 - Józwiak M, Bauer M, Kamysz W et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2)., in the references below
- Combinations add unknowns: interactions, the purity of each ingredient and dosing error.
- No controlled human trial of any research-peptide stack. Published stack protocols describe common practice, not a trial arm. CagriSema is the exception, and it is a manufacturer’s drug.
- Sport rules ban several stack ingredients separately under WADA.
What a careful reader asks
- Is any component an FDA-approved product for this use?
- Is there a primary human study of the combination?
- Who verified identity and purity of each vial?
- Is this a research chemical sold RUO?
Related
- Best peptides by goal, ranked by human evidence
- BPC-157 vs TB-500
- How to read a peptide COA
- Research peptides and the law
- Peptide side effects
To lay out your own stack (totals, vials, and whether two compounds act on the same receptor), use the protocol builder.
Common questions
What is peptide stacking?
Stacking means taking more than one peptide on a shared schedule, either from one pre-mixed vial or from separate vials. It is common among users and in forums, but it is not a standard clinical trial design for unapproved compounds.
What is the best peptide stack for muscle growth?
No stack sold for muscle has been tested as a combination in people. The usual pairing, CJC-1295 with ipamorelin, raises growth hormone and IGF-1 in small studies, but none measured muscle or strength. Tesamorelin has the strongest trials of the growth-hormone peptides, and they measured belly fat in people with HIV, not muscle in healthy adults.
What is the difference between KLOW and GLOW?
Both are vendor-mixed vials of GHK-Cu, BPC-157 and TB-500. KLOW adds a fourth peptide, KPV. Neither combination has been tested in a study, human or animal.
Is a blend vial or separate vials better?
A blend fixes the ratio, so one peptide cannot be changed without changing the others. Separate vials let each peptide be dosed and timed on its own schedule, as with CJC-1295 DAC weekly and ipamorelin daily. Either way, ask for a certificate of analysis that shows each peptide by name and amount.
Is stacking BPC-157 and TB-500 safe?
Neither compound has a robust human safety record yet, and the combination has none. Absence of a known interaction is not the same as evidence of safety.
Do peptide stacks work better?
Nobody has yet run the controlled human trial that would show it for any research-peptide stack. The one animal study of BPC-157 with TB-500 found the pair did no better than TB-500 alone.
References (4 sources)
Bibliographic detail is fetched from PubMed, not written by me - so a citation here cannot drift from the paper it names. Study design comes from PubMed's own tags rather than my judgement.
- 1.Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159.ReviewPMID 30915550
- 2.Józwiak M, Bauer M, Kamysz W et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel). 2025;18(2).ReviewPMID 40005999full text
- 3.WADA 2026 Prohibited List - multiple research peptides prohibited (S0, S2) (national anti-doping agency mirror, PDF).- World Anti-Doping Agency (mirrored by the Jamaica Anti-Doping Commission)regulatory
- 4.FDA warning letter example on research-use peptide marketing and intended use.- US Food and Drug Administrationregulatory